Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:2076
Posts / Week:8.7
Archived Since:November 3, 2010

Blog Post Archive

Some Side Effect For An Antibody

Remember back when AstraZeneca was fighting off Pfizer's ardent, tax-issue-resolving embrace a year ago? One of their weapons was a pitch to their own shareholders about what potential their own pipeline had, and how much of that would presumably go to waste should the deal go through. Show More Summary

The Curse of Expertise

David Sackett, epidemiologist and evidence-based medicine proponent, has died this week. I'd heard of him, but I hadn't seen his editorial about being an expert in one's field. Not all experts have had the thoughts that he had aboutShow More Summary

Targeting Proteins for Destruction

Here's an excellent new paper that's appeared in the preprint area of Science, Science Express. Jay Bradner and co-workers at Harvard/Dana-Farber report a new way to control protein function, and this one seems both very effective and...Show More Summary

A New Amination Reaction

Phil Baran and group have another big new synthetic methods paper out in Science, and it's well worth a look. It's a radical mechanism, based on some earlier work from the group, as you might guess from the conditions: Fe(acac) 2 and triethylsilane in ethanol. Show More Summary

Guess What: Your Peers Are Already Reviewing You

Looks like there are biologists who are getting a chance to figure out what social media can do to communication in their field. Nature News reports on the response to a PNAS paper published late last year from the Mouse ENCODE consortium. Show More Summary

Crappy Antibodies: Available Now, and for the Foreseeable Future

I made a brief mention of this article yesterday, but I wanted to highlight it. It's a look, from Nature New, at the broader implications of the antibody problem in research. Antibodies are, of course, universal reagents in molecular biology assays. Show More Summary

Controlling Proteins, One by One

Here's what looks like a very useful method for turning protein function on and off, reported in a new paper in Nature Chemistry. (This PDF link may work for you). The authors, from the MRC Molecular Biology labs at Cambridge (rightShow More Summary

A Young Blood Controversy

The recent revival of interest in the way that the blood from younger animals (and people?) can improve the health of older ones came bundled with a particular protein candidate for the effect, GDF11. Several papers appeared on its effects...Show More Summary

Pfizer Rumors, Again

Rumors continue to fly around that Pfizer is going to ease its merger hunger and its foreign-cash tax woes by making an offer for GlaxoSmithKline. Lord, what a mess that will be if it happens. Problem is, I can't completely rule that out. Show More Summary

Another Conservation Law

As long as there's been organized scientific research - that is, more than one person working on a problem - there have been timeline disconnects. Something takes longer than expected, throwing everything off, usually. That's the basic...Show More Summary

Nitric Acid And Your Lab Coat

Ah, the good old nitric acid/sulfuric acid nitration conditions. A classic reaction if ever there was one. But you don't want to let it spray all over your lab coat - you really don't. I have a shirt like the coat in that photo, one that I got from a sulfuric acid splashback in 1984 or so. Show More Summary

The Nativis Voyager Appears

To my surprise, there has apparently been a sighting of the "Natavis Voyager" device in the wild. Nativis, as long-time readers will recall, is the company that claims to be able to record "RF signatures" of drugs in solution, which can then be played back at other solutions or organisms to generate the effect of the original drug. Show More Summary

Backstage Problems

This web site has been acting oddly the last day or two - redirects are showing up to totally unrelated domains and so on. But there is indeed a move to a new location coming - archives are being migrated now, and I should be testing out the first version of the new site shortly. Show More Summary

Unkind to Mannkind

Last time I mentioned Mannkind and their inhaled-insulin product (Afrezza) around here was when Oliver Brandicourt was announced as taking over at Sanofi. But I've had unkind things to say about them over the years, and their retail-investor...Show More Summary

Quenching NMRs, Accidentally and On Purpose

You may remember the MRI accident in India, where someone brought an oxygen tank into the imaging room. The consequence were not good ones - not only did two people get pinned to the machine by said tank, it took hours for them to kill...Show More Summary

The Least Useful Element For Organic Chemistry?

I've recently been adding to my list of elements I've worked with, which is a nice effect of my current side project. I'll do an updated post once I total things up; there are some more on order, but I can tell you that I've already checked off a number of the ones mentioned in the 2009 post. Show More Summary

Piling On Andrew Witty

To go along with the recent calls for Andrew Witty to step down at GSK, here's John LaMattina wondering if he's the right guy for the job as well: ...the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering new drugs to patients. Show More Summary

Puma Update: The Roller Coaster Heads Down

There's more news on Puma Biotechnology and their drug, neratinib. It's been quite a story over the last couple of years, and it's not getting any less convoluted. The initial results in breast cancer looked promising, and Puma's stock jumped tremendously. Show More Summary

More Fluorinated Fun

If you're an imaginative organic chemist, you can probably think of some interesting things to do with the never-before-described reagent, difluorodiazomethane. That paper will tell you how to generate it in situ without blowing yourself...Show More Summary

How Not to Handle Your Clinical Data

We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug (Contrave, a sustained release formulation combining the known drugs naltrexone and bupropion) had cardiovascular benefits above and beyond its weight-loss effects. Show More Summary

Copyright © 2015 Regator, LLC